Sold as Stavudine; Lamivudine. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 2 applications for Stavudine; Lamivudine (sold as Stavudine; Lamivudine), with 0 new uses approved and 0 published complete response letters.
| — | Stavudine; LamivudineNDA 21838 | Strides Acrolab | 0 | Discontinued |
| — | Stavudine; LamivudineNDA 22347 | Pharmacare | 0 | Discontinued |
| A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsHIV-1-infection · Gilead Sciences | Phase 4 | Recruiting | Mar 29, 2024 |
| Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVAcquired Immune Deficiency Syndrome (AIDS), HIV Infections · Gilead Sciences | Phase 2 / Phase 3 | Active, not recruiting | Dec 20, 2013 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA